相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Loss of miR-200 Inhibition of Suz12 Leads to Polycomb-Mediated Repression Required for the Formation and Maintenance of Cancer Stem Cells
Dimitrios Iliopoulos et al.
MOLECULAR CELL (2010)
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
Junxia Min et al.
NATURE MEDICINE (2010)
Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines
Mitsutaka Kadota et al.
PLOS ONE (2010)
EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
Mario-Luca Suva et al.
CANCER RESEARCH (2009)
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells
Andrea Viale et al.
NATURE (2009)
F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage
Manas K. Santra et al.
NATURE (2009)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
Xiaojing Yang et al.
PLOS ONE (2009)
Polycomb group proteins: navigators of lineage pathways led astray in cancer
Adrian P. Bracken et al.
NATURE REVIEWS CANCER (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
N. Bucher et al.
BRITISH JOURNAL OF CANCER (2008)
DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications
Xia Jiang et al.
CANCER CELL (2008)
DNA damage detection and repair pathways - Recent advances with inhibitors of checkpoint kinases in cancer therapy
Susan Ashwell et al.
CLINICAL CANCER RESEARCH (2008)
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation
Satoshi Fujii et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Q. Cao et al.
ONCOGENE (2008)
Ribosomal protein s27-like, a p53-inducible modulator of cell fate in response to genotoxic stress
Jingsong Li et al.
CANCER RESEARCH (2007)
Integrative genornics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer
Jinclan Yu et al.
CANCER CELL (2007)
Ubiquitin-independent degradation of cell-cycle inhibitors by the REGγ proteasome
Xueyan Chen et al.
MOLECULAR CELL (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells
Adrian P. Bracken et al.
GENES & DEVELOPMENT (2007)
F-box proteins: the key to protein degradation
MS Ho et al.
JOURNAL OF BIOMEDICAL SCIENCE (2006)
Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress
R Rodriguez et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
F-box proteins: more than baits for the SCF?
Damien Hermand
CELL DIVISION (2006)
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer
H Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells
UK Mukhopadhyay et al.
CANCER RESEARCH (2005)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Regulation of p21WAF1/CIP1 stability by WISp39, a Hsp90 binding TPR protein
T Jascur et al.
MOLECULAR CELL (2005)
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3
R Cao et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2004)
Targeting the checkpoint kinases: Chemosensitization versus chemoprotection
BBS Zhou et al.
NATURE REVIEWS CANCER (2004)
Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe
AN Tse et al.
CANCER RESEARCH (2004)
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints
A Sancar et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
P21 (Waf1/Cip1) as a therapeutic target in breast and other cancers
RH Weiss
CANCER CELL (2003)
Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage
J Seoane et al.
NATURE (2002)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
K Koniaras et al.
ONCOGENE (2001)
The DNA damage response: putting checkpoints in perspective
BBS Zhou et al.
NATURE (2000)
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
PR Graves et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination
RJ Sheaff et al.
MOLECULAR CELL (2000)
分享论文
